Key result
BCOR::CCNB3-positive sarcomas arise primarily in bones and affect young males in ~83% of cases.
Why the study?
BCOR::CCNB3-positive undifferentiated sarcomas are rare tumors with limited clinicopathological, immunohistochemical, molecular, and radiological characterization available.
Population
12 patients with BCOR::CCNB3-positive undifferentiated sarcomas aged 4-17 years
Design
Case series with molecular and radiological analysis
Authors
Loading...
May prompt BCOR testing in young males with bone sarcomas; extends case series but leaves management open.
Case Report (n=12)
BCOR::CCNB3 fusion-positive sarcomas exhibit specific clinicoradiological and histopathological features, and immunohistochemical markers like BCOR, SATB2, and TLE1 are useful for triaging these tumors for molecular testing.
Rekhi et al. (2023) conducted a case report in BCOR::CCNB3-positive sarcomas (n=12). BCOR::CCNB3-positive sarcomas was evaluated. In 12 cases of BCOR::CCNB3-positive sarcomas, tumors predominantly affected young males (10/12) and occurred mostly in bones (9/12), with consistent BCOR::CCNB3 fusion transcript expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: